To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Vaccine Taskforce
Thursday 3rd November 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the expected annual (a) current and (b) capital expenditure on the Vaccines Taskforce will be in each financial year of that project; and if he will place that information in the House of Commons Library.

Answered by Neil O'Brien

On 1 October 2022, the core functions of the Vaccine Taskforce (VTF) merged with the UK Health Security Agency and the Office for Life Sciences.

In February 2022, the National Audit Office confirmed that the VTF’s expenditure on vaccine development and procurement was £3.3 billion to the end of October 2021. In 2022/23, the Department has allocated £2 billion to procure and deploy COVID-19 vaccines


Written Question
Moderna
Wednesday 2nd November 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the status is of the contract to execute the signed Head of Terms from June 2022 between the Government and Moderna for the manufacturer to open a vaccines research and manufacturing centre in the UK.

Answered by Neil O'Brien

In June 2022, the Government agreed a heads of terms with Moderna to create a strategic partnership over the next decade. A full contract is being negotiated, subject to approval of a Full Business Case. The proposed partnership, if agreed, will strengthen domestic mRNA capability and equip the United Kingdom to respond to COVID-19 and future health emergencies.


Written Question
Dementia: Research
Wednesday 26th October 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether it is her Department's policy to double dementia research funding.

Answered by Neil O'Brien

We are continuing to develop our long term plans for dementia, including dementia research.


Written Question
SureScreen Diagnostics
Wednesday 2nd March 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many covid-19 lateral flow tests were supplied to NHS Test and Trace by SureScreen Diagnostics in each month between February 2021 and January 2022.

Answered by Maggie Throup

We are unable to provide the information requested as it is commercially sensitive.


Written Question
Surescreen Diagnostics
Wednesday 26th January 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when approval was sought for the packaging design of covid-19 lateral flow tests by SureScreen Diagnostics; and when that approval was granted.

Answered by Maggie Throup

The Medicines and Healthcare products Regulatory Agency (MHRA) first received an Exceptional Use Authorisation (EUA) application from SureScreen on the 30 September 2021 and after review, approval for the derogation was issued on the 10 November 2021. Whilst we aim to review applications at pace, it is essential that all data is thoroughly assessed.

All packaging and instructions for use are part of the normal review process of an EUA authorisation and the final versions presented to the MHRA were approved on the 23 November 2021.


Written Question
Surescreen Diagnostics
Wednesday 26th January 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when his Department gave approval to SureScreen Diagnostics for the supply of their covid-19 lateral flow tests.

Answered by Maggie Throup

The Medicines and Healthcare products Regulatory Agency (MHRA) first received an Exceptional Use Authorisation (EUA) application from SureScreen on the 30 September 2021 and after review, approval for the derogation was issued on the 10 November 2021. Whilst we aim to review applications at pace, it is essential that all data is thoroughly assessed.

All packaging and instructions for use are part of the normal review process of an EUA authorisation and the final versions presented to the MHRA were approved on the 23 November 2021.


Written Question
Surescreen Diagnostics
Wednesday 26th January 2022

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when SureScreen Diagnostics sought Government approval for the use of their covid-19 lateral flow tests.

Answered by Maggie Throup

The Medicines and Healthcare products Regulatory Agency (MHRA) first received an Exceptional Use Authorisation (EUA) application from SureScreen on the 30 September 2021 and after review, approval for the derogation was issued on the 10 November 2021. Whilst we aim to review applications at pace, it is essential that all data is thoroughly assessed.

All packaging and instructions for use are part of the normal review process of an EUA authorisation and the final versions presented to the MHRA were approved on the 23 November 2021.


Written Question
Test and Trace Support Payment
Friday 15th January 2021

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people have received the Test and Trace Support Payment since its introduction.

Answered by Helen Whately - Minister of State (Department of Health and Social Care)

We are working closely with all 314 lower tier and unitary local authorities to collate information on how the Test and Trace Support Payment scheme is progressing and will release information on the number of applications, number of successful applications and amounts paid out in due course.


Written Question
Epilepsy: Drugs
Tuesday 22nd December 2020

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to (a) reinstate the Quality Outcomes Framework for Epilepsy indicator relating to contraception, conception and pregnancy and (b) give women who are taking anti-epileptic drugs access to pre-conceptional counselling through the Pregnancy Prevention Programme.

Answered by Jo Churchill - Minister of State (Department for Work and Pensions)

The Quality Outcomes Framework (QoF) indicator which focused upon contraception, conception and pregnancy advice was retired in 2014 due to limitations with measurement.

In July 2018, NHS England and Improvement (NHSE/I) published the ‘Report of the Review of the Quality and Outcomes Framework in England.’ This identified a number of principles for the reform of QoF which NHS E/I are continuing to implement, including a focus upon quality improvement activities in areas where metric development is challenging, and upon an increased personalisation of care. The report is available via the link below:

https://www.england.nhs.uk/publication/report-of-the-review-of-the-quality-and-outcomes-framework-in-england/

NHS E/I continue to keep the QoF epilepsy domain under review, and are exploring the potential for new indicators to be developed and implemented.

Every pregnant woman taking the anti-epilepsy drug valproate must be enrolled in the statutory Pregnancy Prevention Programme, and every healthcare professional involved in the prescribing and dispensing of valproate (so for example GPs and pharmacists) must ensure women are aware of the serious risks to pregnancy valproate presents.

Following advice from the Commission on Human Medicines, the available data relating to safety of use of non-valproate epileptic medicines during pregnancy is currently being evaluated. As part of this review, the product information for prescribers and patients will be evaluated to ensure that it is clear and up to date, including the need for preconception counselling, as appropriate. The communications from this review will be made publicly available in order to support informed decision making about the most appropriate choice of antiepileptic treatment in the individual case.


Written Question
NHS and Social Care Coronavirus Life Assurance Scheme 2020
Tuesday 15th December 2020

Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many applications have been (a) made to and (b) accepted by the NHS and Social Care Coronavirus Life Assurance Scheme to date.

Answered by Helen Whately - Minister of State (Department of Health and Social Care)

As of 9 December, 268 claims have been received in England. 228 claims have been accepted for payment and the remainder are going through the stages of being processed and assessed.